E.U. Expands Antitrust Review Of Guidant Deal
The delay will cost Boston Scientific tens of millions of dollars. The company had held out hopes of completing the deal by March 30, but conceded that might change after the company made certain commitments to the Commission last week.
The commitments were intended to alleviate the Commission's antitrust concerns.
The Commission’s announcement has pushed the...
To view the full article, register now.